Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the pri

TD Cowen analyst Joseph Thome maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price tar

Ardelyx, Inc. (ARDX) Q2 2026 Earnings Call Transcript

BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price targ

Gainers Doximity (NYSE:DOCS) stock rose 85.1% to $38.25 during Friday's pre-market session. The

US stock futures mixed, Nasdaq 100 futures up 100 points. Trade Desk Inc shares down 27.7% after wea

ARDX, ARDT and GPRE have been added to the Zacks Rank #5 (Strong Sell) List on August 7th, 2026.

Atlassian Corp (NASDAQ: TEAM) reported strong Q4 results, beating revenue and earnings estimates. St

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed

Ardelyx NASDAQ: ARDX reported second-quarter product revenue of $118 million, up 31% from a year ear

Gainers Doximity (NYSE:DOCS) stock increased by 65.6% to $34.22 during Thursday's after-market

Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.07) per share which missed the analyst consen

ARDX, BDORY and AXSM have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2026.

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX) (“Ardelyx” or the “Co

ABR, ARDX and RGNX have been added to the Zacks Rank #5 (Strong Sell) List on July 23, 2026.

According to an SEC filing, an executive at Ardelyx reported selling 81,898 directly held Common Sto

Ladenburg Thalmann analyst Caroline Palomeque assumes Ardelyx (NASDAQ:ARDX) with a Buy rating and

Ardelyx NASDAQ: ARDX executives said at the Jefferies Global Healthcare Conference that the company

WALTHAM, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Com

Ardelyx (ARDX) is rated Buy, driven by robust commercial execution of IBSRELA and XPHOZAH, and manag

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Dru

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage bi

Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript

Ardelyx (ARDX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate

While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed

Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.15) per share which missed the analyst consen

Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year IBSRELA Q1 2026

Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earn

Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition b

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earning

WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commerciali

Ardelyx stock drops premarket despite revenue beat as investors weigh IBSRELA growth outlook and mix

HC Wainwright & Co. analyst Matthew Caufield maintains Ardelyx (NASDAQ:ARDX) with a Buy and r

Ardelyx (NASDAQ:ARDX) reported quarterly earnings of $0.00 per share which missed the analyst consen

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develo